A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

Summary

The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).

Timeline

Start

2023-02-13

Primary completion

2024-02-20

Completion

2024-03-12

Drugs

Indications